Search Results - "Modesti, Mikol"

Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer by Nuzzo, Pier Vitale, Pederzoli, Filippo, Saieva, Calogero, Zanardi, Elisa, Fotia, Giuseppe, Malgeri, Andrea, Rossetti, Sabrina, Valenca Bueno, Loana, Andrade, Livia Maria Q S, Patrikidou, Anna, Mestre, Ricardo Pereira, Modesti, Mikol, Pignata, Sandro, Procopio, Giuseppe, Fornarini, Giuseppe, De Giorgi, Ugo, Russo, Antonio, Francini, Edoardo

“…Metastatic castration-resistant prostate cancer remains a challenging condition to treat. Among the available therapeutic options, the androgen receptor…”
Get full text

Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer by Nuzzo, Pier Vitale, Ravera, Francesco, Saieva, Calogero, Zanardi, Elisa, Fotia, Giuseppe, Malgeri, Andrea, Rossetti, Sabrina, Valença, Loana Bueno, El Zarif, Talal, Davidsohn, Matthew P., McClure, Heather, Oliveira, Thiago Martins, Vauchier, Charles, Pereira Mestre, Ricardo, Modesti, Mikol, Ravi, Praful, Patrikidou, Anna, Pignata, Sandro, Procopio, Giuseppe, Fornarini, Giuseppe, De Giorgi, Ugo, Russo, Antonio, Francini, Edoardo

“…Background: Androgen receptor signaling inhibitors (ARSis) abiraterone acetate (AA) plus prednisone and enzalutamide (Enza), are currently the most…”
Get full text

Clinical outcomes of abiraterone acetate (AA) or enzalutamide (E) as first-line therapy (Rx) for men aged ≥75 with metastatic castration-resistant prostate cancer (mCRPC) according to previous use of docetaxel (D) for metastatic castration-sensitive prostate cancer (mCSPC) in a multicenter international registry: A SPARTACUSS – Meet-URO 26 study by Lee-Ying, Richard M., Saieva, Calogero, Nuzzo, Pier Vitale, Malgeri, Andrea, Fotia, Giuseppe, Zanardi, Elisa, Rossetti, Sabrina, Valenca, Loana Bueno, Patrikidou, Anna, Modesti, Mikol, Martins Oliveira, Thiago, Pignata, Sandro, Fornarini, Giuseppe, Procopio, Giuseppe, Santini, Daniele, Sweeney, Christopher, Heng, Daniel Yick Chin, De Giorgi, Ugo, Russo, Antonio, Francini, Edoardo

“…107 Background: The optimal management of mCRPC in men aged ≥75 is challenging, and there is a paucity of clinical data in the literature. Although AA and E…”
Get full text

Antiandrogens as Therapies for COVID-19: A Systematic Review by Cani, Massimiliano, Epistolio, Samantha, Dazio, Giulia, Modesti, Mikol, Salfi, Giuseppe, Pedrani, Martino, Isella, Luca, Gillessen, Silke, Vogl, Ursula Maria, Tortola, Luigi, Treglia, Giorgio, Buttigliero, Consuelo, Frattini, Milo, Pereira Mestre, Ricardo

“…In 2019, the breakthrough of the coronavirus 2 disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),…”
Get full text

Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS—Meet-URO 26 Study by Fotia, Giuseppe, Saieva, Calogero, Lee-Ying, Richard, Patrikidou, Anna, Nuzzo, Pier Vitale, Zanardi, Elisa, Rossetti, Sabrina, Davidsohn, Matthew, Eid, Marc, El Zarif, Talal, McClure, Heather, Spinelli, Gian Paolo, Damassi, Alessandra, Murianni, Veronica, Vauchier, Charles, Oliveira, Thiago Martins, Malgeri, Andrea, Modesti, Mikol, Mestre, Ricardo Pereira, Valenca, Loana, Ravi, Praful, Santini, Daniele, Pignata, Sandro, De Giorgi, Ugo, Sweeney, Christopher, Heng, Daniel, Procopio, Giuseppe, Russo, Antonio, Francini, Edoardo

“…Managing metastatic castration-resistant prostate cancer (mCRPC) in men aged ≥ 75 is challenging due to limited data. Regardless of age, in real-world clinical…”
Get full text

Clinical outcomes of volume of disease on patients receiving enzalutamide abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer by Pier Vitale Nuzzo, Francesco Ravera, Calogero Saieva, Elisa Zanardi, Giuseppe Fotia, Andrea Malgeri, Sabrina Rossetti, Loana Bueno Valença, Talal El Zarif, Matthew P. Davidsohn, Heather McClure, Thiago Martins Oliveira, Charles Vauchier, Ricardo Pereira Mestre, Mikol Modesti, Praful Ravi, Anna Patrikidou, Sandro Pignata, Giuseppe Procopio, Giuseppe Fornarini, Ugo De Giorgi, Antonio Russo, Edoardo Francini

“…Background: Androgen receptor signaling inhibitors (ARSis) abiraterone acetate (AA) plus prednisone and enzalutamide (Enza), are currently the most…”
Get full text